Lars Rydén

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Lars Rydén, Peter J. Grant, Stefan D. Anker et al. · European Heart Journal · 2013 · 1.9K citations · Full text

Metabolic Syndrome, Diabetes Management, Diabetes Epidemiology +11

Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year

Klas Malmberg, Lars Rydén, Suad Efendić et al. · Journal of the American College of Cardiology · 1995 · 1.6K citations

Diabetes Management, Cardiovascular Disease, Insulin Management +8

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

K. Malmberg, Lars Rydén, Hans Wedel et al. · European Heart Journal · 2005 · 1.1K citations · Full text

EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries

Kornelia Kotseva, David Wood, Dirk De Bacquer et al. · European Journal of Preventive Cardiology · 2015 · 985 citations · Full text